Desunin 800IU Tablets

Product Information *

  • Company:

    Mylan IRE Healthcare Limited
  • Status:

    No Recent Update
  • Active Ingredients * :

    *Additional information is available upon request

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 28 January 2021

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 28 January 2021

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision

Updated on 22 March 2019

Reasons for updating

  • New PIL for new product

Updated on 21 March 2019

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 May 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 15 May 2017

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 10: date of revision has changed

Updated on 15 May 2017

Reasons for updating

  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 10: date of revision has changed

Updated on 13 July 2016

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 1: Slight text amendment

In section 4.1: Further text added to the therapeutic indications.

In section 4.2: Change in information for posology.

In section 4.4: Removal of text as it is moved to section 4.2

In section 4.8: Addition of ADR statement.

In section 5.3: Minor typographical correction.

In section 6.1: Change in description of one of the excipients.

In section 10: The date of revision has been changed.

Updated on 13 July 2016

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 1: Slight text amendment

In section 4.1: Further text added to the therapeutic indications.

In section 4.2: Change in information for posology.

In section 4.4: Removal of text as it is moved to section 4.2

In section 4.8: Addition of ADR statement.

In section 5.3: Minor typographical correction.

In section 6.1: Change in description of one of the excipients.

In section 10: The date of revision has been changed.

Updated on 08 September 2014

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.4: the storage conditions have changed from ‘Do not store above 25°C’ to ‘Do not store above 30°C’.

In section 10: the date of revision has changed.

Updated on 08 September 2014

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.4: the storage conditions have changed from ‘Do not store above 25°C’ to ‘Do not store above 30°C’.

In section 10: the date of revision has changed.

Updated on 10 June 2014

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.3: the shelf life has increased to 3 years from 2 years
In section 10: the date of revision has changed to June 2014

Updated on 10 June 2014

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.3: the shelf life has increased to 3 years from 2 years
In section 10: the date of revision has changed to June 2014

Updated on 18 July 2013

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.3: The shelf-life of Desunin has been extended from 18 months to 2 years.

In section 10: The date of revision has been changed.

Updated on 18 July 2013

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.3: The shelf-life of Desunin has been extended from 18 months to 2 years.

In section 10: The date of revision has been changed.

Updated on 06 November 2012

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 06 November 2012

Reasons for updating

  • New SPC for new product

Free text change information supplied by the pharmaceutical company

None provided